US-based gene sequencing company Sequenom was handed a win yesterday after a UK court ruled that The Doctors Laboratory and Ariosa Diagnostics, which is owned by Roche, had infringed its patent.
A group of more than 100 medical, scientific, patient advocacy and women’s health organisations have opposed a recent proposal to amend section 101 of the US Patent Act.
Danish research company Bioneer has secured a non-exclusive licence to CRISPR/Cas9 technology owned by French geneticist Emmanuelle Charpentier.
Biopharmaceutical company Sensorion has entered into a research collaboration with French research body Institut Pasteur.
A subsidiary of China-based genome sequencing company BGI has filed a patent infringement suit against a US competitor.
The US Patent and Trademark Office has issued a new CRISPR/Cas9 patent to the University of California, the University of Vienna and microbiologist Emmanuelle Charpentier.
Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.
ERS Genomics has announced a new CRISPR/Cas9 US patent for use of the gene-editing technology in a single guide format.
The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.
Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.